Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the clinical results of anti-VEGF intra-vitreal injections (IVT) in CNV secondary to pathologic myopia (PM-CNV).


Clinical Trial Description

Twenty consecutive patients (30 eyes) with subfoveal PM-CNV, 9 of whom had been unsuccessfully treated with Visudyne PDT, were treated with IVT of 0.5mg ranibizumab. ETDRS best corrected visual acuity, macular thickness on OCT scans, and angiographic features were recorded and evaluated. The aspect of OCT scans passing across the PM-CNV was also analyzed. IVTs were repeated only in case of persistent angiographic leakage and if OCT scans showed retinal thickening or edema and serous retinal detachment. The follow-up period was at least 6 months. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01246089
Study type Interventional
Source Instituto de Olhos de Goiania
Contact
Status Active, not recruiting
Phase Phase 4
Start date July 2009
Completion date November 2014

See also
  Status Clinical Trial Phase
Completed NCT04524910 - A Study to Learn More About How Drug Aflibercept Works in Canadian Patients With Reduced Vision Caused by New Blood Vessels Growing in the Eye (Myopic Choroidal Neovascularization or mCNV)
Completed NCT02175940 - VEGF and PEDF in Patients With Myopic Choroidal Neovascularization N/A
Completed NCT00797992 - Bevacizumab Intravitreal for Myopic Choroidal Neovascularization Phase 4